Lagevrio 01
Lagevrio Capsule
Product Images NDC 0006-5055
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Lagevrio (NDC 0006-5055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Lagevrio 02
This text appears to be a table containing various parameters and their values related to a clinical trial for a drug called LAGEVRIO. The parameters listed in the table include the time from symptom onset to randomization, age, sex, obesity, diabetes mellitus, baseline COVID severity, baseline clades, baseline antibody status, and a comparison of the number of events and subjects between LAGEVRIO and placebo. The table also presents the risk differences in percentage values along with their 95% confidence intervals.*
Lagevrio 03
Lagevrio is a medication available in capsule form containing 200mg molnupiravir for use under Emergency Use Authorization. It is recommended to store the capsules between 20°C to 25°C (68°F to 77°F). The medication is only available with a prescription and should be dispensed in its original container. The box contains 40 capsules. The package provides a QR code or a URL to access the FDA-authorized Fact Sheet for dosage and administration. The text also includes details about the GTIN code, the manufacturer, and encoding area for 2D Serialization Barcode, Serial Number, Expiry, and Lot information.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
